First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee(Washington University in St. Louis), Jeffrey S. Miller(Science Museum of Minnesota), Rachel L. Kyllo, Amanda F. Cashen(Washington University in St. Louis), András Schaffer, Milan J. Anadkat(Washington University in St. Louis), Amy Musiek(Washington University in St. Louis), Daniel D. Miller(University of Minnesota), Bruce R. Blazar(University of Minnesota Medical Center), Sithara Vivek(University of Minnesota Medical Center), John F. DiPersio(Washington University in St. Louis), Emily K. Jeng(Altor BioScience (United States)), Hing C. Wong(Heat Biologics (United States)), Daniel J. Weisdorf(University of Minnesota), Celalettin Üstün(Rush University Medical Center), Jack O. Egan(Altor BioScience (United States)), Ilana S. Rosman(Harvard University), Todd E. DeFor(NHS Blood and Transplant), Melissa M. Berrien-Elliott(Washington University in St. Louis), Lindsey Peck(Washington University in St. Louis), Sarah Cooley(Palmetto Hematology Oncology), John E. Wagner(Kings County Hospital Center), Peter Westervelt(MACOM (United States)), Michael R. Verneris(NHS Blood and Transplant), Amy D. Rock(Altor BioScience (United States)), Todd A. Fehniger(Washington University in St. Louis)
Cited by 406
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance
|Immunity|2007|988
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|Science Translational Medicine|2016|916